Phase 3 ePHex Study: OxThera Reports Results
Sid Martin Biotech alum OxThera AB, a biopharma company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces results of its pivotal Phase 3 study.
New OxThera/Oxabact US Patent Granted
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.
